OOIR: Observatory of International Research

Papers

(The H4-Index of Headache is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Headaches Associated With Personal Protective Equipment – A Cross‐Sectional Study Among Frontline Healthcare Workers During COVID‐19	313
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice	275
COVID‐19 is a Real Headache!	176
The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic‐specific estimates from government health surveys	120
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review	93
The Role of Diet and Nutrition in Migraine Triggers and Treatment: A Systematic Literature Review	83
Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine	82
Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers	78
Headaches During COVID‐19: My Clinical Case and Review of the Literature	70
Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study	70
Headache as a Cardinal Symptom of Coronavirus Disease 2019: A Cross‐Sectional Study	62
Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study	61
Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?	57
High Prevalence of Headaches During Covid‐19 Infection: A Retrospective Cohort Study	56
Hypertension: A new safety risk for patients treated with erenumab	56
Spectrum of Headaches Associated With SARS‐CoV‐2 Infection: Study of Healthcare Professionals	55
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2	54
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine	53
COVID‐19 and Headache: A Primer for Trainees	53
Case Series of Headache Characteristics in COVID‐19: Headache Can Be an Isolated Symptom	52
Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study	49
Chronic versus episodic migraine: The 15‐day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency	46
Migraine and Ischemic Stroke in Women. A Narrative Review	44
Persistent Headache and Persistent Anosmia Associated With COVID‐19	44
Frequency and Type of Red Flags in Patients With Covid‐19 and Headache: A Series of 104 Hospitalized Patients	42

Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta‐Analysis	42
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients	40
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study	40
Headache associated with COVID‐19: Epidemiology, characteristics, pathophysiology, and management	40
Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study	40
The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study	40
Toward a better understanding of persistent headache after mild COVID‐19: Three migraine‐like yet distinct scenarios	39
Alterations in Brain Function After Cognitive Behavioral Therapy for Migraine in Children and Adolescents	38
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1	37
Headache attributed to idiopathic intracranial hypertension and persistent post‐idiopathic intracranial hypertension headache: A narrative review	37
Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire	35
Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study	35